+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review

  • PDF Icon

    SWOT Analysis

  • 47 Pages
  • June 2023
  • GlobalData
  • AnaptysBio Inc
  • ID: 4395070
AnaptysBio Inc (ANAB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the publisher to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description - A detailed description of the company’s operations and business divisions.
  • Corporate strategy - Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history - Progression of key events associated with the company.
  • Major products and services - A list of major products, services and brands of the company.
  • Key competitors - A list of key competitors to the company.
  • Key employees - A list of the key executives of the company.
  • Executive biographies - A brief summary of the executives’ employment history.
  • Key operational heads - A list of personnel heading key departments/functions.
  • Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
  • Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

AnaptysBio Inc (AnaptysBio) is a clinical-stage biotechnology company that focuses on the development of antibody candidates for the treatment of atopic dermatitis, ovarian cancer, lung cancer, asthma, psoriasis, inflammation and other autoimmune indications. The company develops its product candidates through its proprietary antibody discovery technology platform that is based on somatic hypermutation (SHM). The company has various product candidates under development for the treatment of moderate-to-severe adult atopic dermatitis, asthma, generalized pustular psoriasis and palmo-plantar pustular psoriasis, and human autoimmune diseases. The company has partnership with GlaxoSmithKline and Bristol-Myers Squibb to develop its product candidates. AnaptysBio is headquartered in San Diego, California, the US.

AnaptysBio Inc Key Recent Developments

May 11, 2023: AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
Mar 01, 2023: AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Aug 08, 2022: AnaptysBio announces second quarter 2022 financial results and provides pipeline update
May 04, 2022: AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company

Table of Contents

Section 1 - About the Company
  • AnaptysBio Inc - Key Facts
  • AnaptysBio Inc - Key Employees
  • AnaptysBio Inc - Key Employee Biographies
  • AnaptysBio Inc - Major Products and Services
  • AnaptysBio Inc - History
  • AnaptysBio Inc - Company Statement
  • AnaptysBio Inc - Locations And Subsidiaries
  • Head Office
  • Other Locations & Subsidiaries
Section 2 - Company Analysis
  • Company Overview
  • AnaptysBio Inc - Business Description
  • R&D Overview
  • AnaptysBio Inc - Corporate Strategy
  • AnaptysBio Inc - SWOT Analysis
  • SWOT Analysis - Overview
  • AnaptysBio Inc - Strengths
  • AnaptysBio Inc - Weaknesses
  • AnaptysBio Inc - Opportunities
  • AnaptysBio Inc - Threats
  • AnaptysBio Inc - Key Competitors
Section 3 - Company Financial Ratios
  • Financial Ratios - Capital Market Ratios
  • Financial Ratios - Annual Ratios
  • Performance Chart
  • Financial Performance
  • Financial Ratios - Interim Ratios
  • Financial Ratios - Ratio Charts
Section 4 - Company’s Lifesciences Financial Deals and Alliances
  • AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • AnaptysBio Inc, Recent Deals Summary
Section 5 - Company’s Recent Developments
  • May 11, 2023: AnaptysBio Announces First Quarter 2023 Financial Results and Provides Pipeline Update
  • Mar 01, 2023: AnaptysBio Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
  • Aug 08, 2022: AnaptysBio announces second quarter 2022 financial results and provides pipeline update
  • May 04, 2022: AnaptysBio Announces First Quarter 2022 Financial Results and Provides Pipeline Update
  • Mar 21, 2022: AnaptysBio appoints Daniel Faga as Interim Chief Executive Officer
  • Mar 07, 2022: AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Update
Section 6 - Appendix
  • Methodology
  • Ratio Definitions
  • About the Publisher
  • Contact the Publisher
  • Disclaimer
List of Tables
  • AnaptysBio Inc, Key Facts
  • AnaptysBio Inc, Key Employees
  • AnaptysBio Inc, Key Employee Biographies
  • AnaptysBio Inc, Major Products and Services
  • AnaptysBio Inc, History
  • AnaptysBio Inc, Subsidiaries
  • AnaptysBio Inc, Key Competitors
  • AnaptysBio Inc, Ratios based on current share price
  • AnaptysBio Inc, Annual Ratios
  • AnaptysBio Inc, Interim Ratios
  • AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2017 to YTD 2023
  • AnaptysBio Inc, Recent Deals Summary
  • Currency Codes
  • Capital Market Ratios
  • Equity Ratios
  • Profitability Ratios
  • Cost Ratios
  • Liquidity Ratios
  • Leverage Ratios
  • Efficiency Ratios
List of Figures
  • AnaptysBio Inc, Performance Chart (2018 - 2022)
  • AnaptysBio Inc, Ratio Charts
  • AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2017 to YTD 2023
  • AnaptysBio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2017 to YTD 2023

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Eli Lilly and Co
  • Janssen Pharmaceuticals Inc
  • Novartis AG
  • Janssen Pharmaceuticals Inc
  • Eli Lilly and Co
  • Amgen Inc
  • Sanofi
  • GSK plc
  • F. Hoffmann-La Roche Ltd
  • Regeneron Pharmaceuticals Inc
  • Boehringer Ingelheim International GmbH
  • AstraZeneca Plc
  • Pandion Therapeutics Inc
  • AbbVie Inc
  • Pandion Therapeutics Inc
  • AbbVie Inc
  • Regeneron Pharmaceuticals Inc
  • AstraZeneca Plc
  • Novartis AG
  • Amgen Inc
  • Boehringer Ingelheim International GmbH
  • GSK plc
  • Sanofi
  • F. Hoffmann-La Roche Ltd